Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOL-DP-o-05 for preservation of beta-cell function in newly-diagnosed T1DM
NCT04102202Phase 2Withdrawn
- Sponsor
- BOL Pharma
- Start
- Nov 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of A5 in type 1 diabetes mellitus (T1D), sponsored by BOL Pharma. Planned start Nov 2020; status: withdrawn.
02
Drugs
A5
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04102202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102202.